Zimbabwe: Fears Mount Over Drug-Resistant HIV
[The Herald] At least 60 percent of people living with HIV in Sub-Saharan Africa, including Zimbabwe, are becoming resistant to the key anti-retroviral drug, Tenofovir, raising fears among scientists that a strain of virus resistant to drugs might have developed. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - February 9, 2016 Category: Infectious Diseases Source Type: news
HIV: Tenofovir Resistance Higher Than ExpectedHIV: Tenofovir Resistance Higher Than Expected
A study has found that resistance to tenofovir, often used in first-line treatment in adults with HIV-1, is higher than expected, especially in sub-Saharan Africa. Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 5, 2016 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Resistance to HIV Drug Growing, Study Finds
Problem affects almost two-thirds of those taking tenofovir in sub-Sahara Africa (Source: Fertility News - Doctors Lounge)
Source: Fertility News - Doctors Lounge - January 29, 2016 Category: Reproduction Medicine Authors: webmaster at doctorslounge.com Tags: Pharmacy, Reproductive Medicine, AIDS, News, Source Type: news
Resistance to HIV Drug Growing, Study Finds
Problem affects almost two-thirds of those taking tenofovir in sub-Sahara Africa (Source: WebMD Health)
Source: WebMD Health - January 29, 2016 Category: Consumer Health News Source Type: news
Resistance to HIV Drug Growing, Study Finds
Problem affects almost two-thirds of those taking tenofovir in sub-Sahara Africa
Source: HealthDay
Related MedlinePlus Pages: HIV/AIDS, HIV/AIDS Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - January 29, 2016 Category: Consumer Health News Source Type: news
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study
This study examines how strains of HIV are becoming resistant to an antiretroviral drug commonly used to prevent and fight the virus, research has suggested HIV was resistant to the drug Tenofovir in 60% of cases in several African countries, covering the period 1998 to 2015. The research, led by University College London, looked at around 2,000 HIV patients worldwide. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 29, 2016 Category: Consumer Health News Source Type: news
Study: HIV becoming resistant to key drug
Stephen FellerLONDON, Jan. 28 (UPI) -- HIV is becoming resistant to tenofovir, a key antiretroviral drug, due to improper or inconsistent use, according to a new study. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 28, 2016 Category: Consumer Health News Source Type: news
Resistance to key HIV drug 'concerningly common'
(University College London) HIV drug resistance to tenofovir, an antiretroviral drug vital to most modern HIV treatment and prevention strategies, is surprisingly and worryingly common according to a large study led by UCL and funded by the Wellcome Trust. The research, co-authored by researchers at Stanford University and the London School of Hygiene and Tropical Medicine and published in the Lancet Infectious Diseases journal, studied 1,926 HIV patients across the world with uncontrolled HIV despite being prescribed antiretrovirals. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 28, 2016 Category: Infectious Diseases Source Type: news
Genvoya (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 30, 2015 Category: Drugs & Pharmacology Source Type: news
Population Council's MZC outperforms TFV 1 percent gel in microbicide candidate preclinical study
(Population Council) New data from a preclinical safety and efficacy study of the candidate microbicide gel MZC, which targets HIV, herpes simplex virus and human papillomavirus, shows that the gel performs as well as, or in many cases, better than, tenofovir 1 percent gel, a leading microbicide candidate. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 25, 2015 Category: Infectious Diseases Source Type: news
Tenofovir Prevents HBV Transmission in Pregnancy
(MedPage Today) -- Safe and well tolerated when started weeks 30 to 32 gestation (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 20, 2015 Category: Gastroenterology Source Type: news
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Now Included Among Recommended Regimens for Antiretroviral Treatment-Naive Individuals with HIV-1 Infection
The FDA recently approved the fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (EVG/c/FTC/TAF) as a complete regimen for antiretroviral treatment (ART)-naive HIV-infected individuals 12 years or older. Based on efficacy and safety data from phase 3 randomized clinical trials, the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents will include EVG/c/FTC/TAF among the Recommended Initial Regimens for ART-naive adults and adolescents with estimated creatinine clearance ≥ 30 mL/min (AI). For more information, see the Panel’s statement on EVG/c/FTC/TAF. (Source...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - November 20, 2015 Category: Infectious Diseases Source Type: news
New single-dose HIV drug Genvoya is approved by the FDA
Genvoya, which contains the antiviral medication tenofovir, enters the body's cells, including those infected with HIV and those where the virus replicates, more efficiently than current drugs. (Source: the Mail online | Health)
Source: the Mail online | Health - November 7, 2015 Category: Consumer Health News Source Type: news
Tenofovir linked with acute kidney injury in HIV-infected patients
Acute kidney injury (AKI) associated with tenofovir disoproxil fumarate (TDF) was prevalent among HIV-infected patients and demonstrated a high morbidity rate in a new center-based study. More than half of patients with TDF-associated AKI did not recover baseline kidney function during follow-up, and about one-third of the patients required dialysis, according to new research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 6, 2015 Category: Science Source Type: news
FDA Clears New Combo Pill Genvoya for HIV-1 InfectionFDA Clears New Combo Pill Genvoya for HIV-1 Infection
Genvoya combines elvitegravir, cobicistat, emtricitabine, and a new form of tenofovir, which appears to have a better safety profile than tenofovir disoproxil fumarate. FDA Approvals (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - November 6, 2015 Category: Pediatrics Tags: HIV/AIDS News Alert Source Type: news
